Person: ERBAY, MÜGE
Loading...
Email Address
Birth Date
4 results
Search Results
Now showing 1 - 4 of 4
Publication Fatigue: A forgotten symptom of asthma(Wiley, 2021-03-29) Günaydın, Fatma Esra; Ediger, Dane; Erbay, Müge; GÜNAYDIN, FATMA ESRA; EDİGER, DANE; ERBAY, MÜGE; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı/İmmünolji ve Alerji Hastalıkları Bölümü; 0000-0002-9268-1071; 0000-0002-2954-4293; 0000-0003-3948-7007; HKV-2265-2023; HJA-1363-2022; AAE-9142-2019Objective Fatigue is a common symptom frequently reported in many disorders but little is known about the prevalence of fatigue in asthma. The objective of this study was to determine the prevalence of fatigue in asthmatic patients, the effect of fatigue on asthma quality of life and the relationship between fatigue and anxiety/depressionMaterials and methods This prospective cross-sectional study was conducted in Uludag University Faculty of Medicine, Department of Immunology and Allergic Diseases outpatient clinic from June 2019 to December 2019. Fatigue was assessed using the Checklist Individual Strength-Fatigue (CIS-Fatigue), psychological distress was assessed using the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI) and quality of life were assessed using the Asthma Quality of Life Questionnaire (AQLQ).Results In the present study, a total of 168 patients are included with an average age of 43.8 +/- 4.3 years. Nearly 64.8% of patients had controlled asthma and (35.2%) patients had uncontrolled asthma. Fatigue (CIS-Fatigue >= 27 points) was detected in 62.6% of patients and associated with asthma-related quality of life, asthma control, dyspnea, depression and anxiety (P < 0.05). However, the degree of lung function impairment and asthma severity were not associated with fatigue.Conclusions Fatigue as a symptom is common in asthmatic patients and correlates with asthma-related quality of life, asthma control, dyspnea, depression and anxiety. Future studies are needed to better understand the physical, psychological, behavioural and systemic factors that precipitate or perpetuate fatigue in asthma.Publication Fatigue: A forgotten symptom of asthma(Wiley, 2021-11-01) Gunaydin, Fatma Esra; Ediger, Dane; Erbay, Müge; GÜNAYDIN, FATMA ESRA; EDİGER, DANE; ERBAY, MÜGE; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı/İmmünoloji ve Alerji Bilim Dalı.; 0000-0002-9268-1071; 0000-0002-2954-4293; HKV-2265-2023; AAE-9142-2019; IKM-5924-2023Publication Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab(Turkish Assoc Tuberculosis & Thorax, 2023-01-01) Pekbak, Gülseren; PEKBAK, GÜLSEREN; Ediger, Dane; ERBAY, MÜGE; Günaydın, Fatma Esra; GÜNAYDIN, FATMA ESRA; Erbay, Müge; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Alerji ve İmmunoloji Anabilim Dalı.; 0000-0002-2954-4293; 0000-0002-9268-1071; HJA-1363-2022Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumabIntroduction: Omalizumab, a humanized monoclonal anti-IgE antibody, has largely demonstrated its efficacy in severe allergic asthma. There are limited data about the effectiveness of omalizumab in patients with non-atopic severe persistent asthma. In this study, we aimed to determine the effect of omalizumab in patients with non-atopic severe asthma and compare the data obtained with those in patients with allergic severe asthma.Materials and Methods: This study was an observational, retrospective, tertiary single-center study that assessed and compared the clinical outcome of adult patients with severe asthma (165 atopic and 41 non-atopic) who have been on omalizumab for one year or longer between January 2008 and January 2020. Effectiveness was assessed by considering symptom scores (GINA symptom control score), daily systemic corticosteroids (SCS) dosage, blood eosinophil counts, pulmonary function, and number of severe exacerbations and hospitalizations within the last one year.Results: Omalizumab exhibited significant improvement in the clinical status of non-atopic asthma patients as measured by GINA symptom score [decreased from 3.77 +/- 0.63 to 1.36 +/- 1.27 (p< 0.001)], the number of emergency room visits for asthma [decreased from 11.25 +/- 14.69 to 0.25 +/- 0.55 (p< 0.001)], and the number of hospitalizations [decreased from 1.17 +/- 2.87 to 0.14 +/- 0.36 (p= 0.036)]. These results were not significantly different from those obtained in allergic asthma patients. FEV1 improved significantly from 2.08 +/- 0.86 to 2.14 +/- 0.84 (p= 0.041) and oral corticosteroid doses decreased significantly from 1.67 +/- 7.49 to 0.46 +/- 2.74 (p= 0.015) in the only atopic group.Conclusion: Omalizumab, which is a proven and effective treatment option for allergic asthma, may also be an efficacious alternative option in non-atopic severe asthma.Publication Efficacy of omalizumab treatment in patients with asthma-chronic obstructive pulmonary disease overlap (aco)(Bilimsel Tip Yayinevi, 2022-01-19) Ediger, Dane; EDİGER, DANE; Erbay, Müge; ERBAY, MÜGE; Şeker, Ümmühan; ŞEKER, ÜMMÜHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-2954-4293; AAE-9142-2019; HJA-1363-2022; JCN-9554-2023Objective: Although the precise definition of asthma-chronic obstructive pulmonary disease overlap (ACO) is still controversial, patients sharing common features of both diseases are frequently seen in clinical practice. Current literature suggests that patients with ACO have higher risk of morbidity and mortality than those with asthma or chronic obstructive pulmonary disease (COPD) alone. Omalizumab, a monoclonal anti-IgE monoclonal antibody, has proven to be effective in moderate-to-severe allergic asthma, but data on the efficacy of omalizumab in patients with ACO are limited. To determine the efficacy of omalizumab in patients with ACO.Materials and Methods: We assessed the effectiveness of omalizumab on 12 patients who met the criteria of ACO, using data from medical files of patients with severe allergic asthma who were treated with omalizumab between 2013 and 2018 at a University hospital.Results: Five (41.7%) patients responded well and seven (58.3%) patients responded partially to omalizumab treatment. Decreased number of hospitalizations and exacerbations (p = 0.016 and p = 0.003, respectively) and increased asthma control test results (ACT) (p=0.003) were observed after omalizumab treatment. No significant improvement in pulmonary function tests (FEV1%, FEV1(liter), FEV1/FVC) was found (p=0.444, p=0.208, p=0.510, respectively).Conclusion: Omalizumab was found to reduce asthma exacerbations and improve asthma control in a group of patients with ACO.